Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00279760 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 210
- Enrollment target
NCT00279760: Completed Phase 1 study, sponsored by Bristol-Myers Squibb.
NCT00279760 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 210 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (250% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00279760, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 210 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo controlled, parallel and multiple dose study provided safety, preliminary efficacy, and immunogenicity information about the use of BMS-188667 and BMS-224818 in subjects with RA
Interventions
- DRUG Abatacept
- DRUG Belatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Phase | Phase 1 |
What the finished NCT00279760 record still lists
NCT00279760 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (250% higher).
The record links to 0 conditions, and to 2 interventions - of which Abatacept is the first listed.
NCT00279760 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00279760 about?
NCT00279760 is a clinical study titled "Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis". This randomized, double-blind, placebo controlled, parallel and multiple dose study provided safety, preliminary efficacy, and immunogenicity information about the use of BMS-188667 and BMS-224818 in subjects with RA
What is the current status of trial NCT00279760?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 210 participants.
What interventions are being tested in trial NCT00279760?
The interventions under investigation include: Abatacept (DRUG), Belatacept (DRUG).
Who is sponsoring clinical trial NCT00279760?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00279760's enrollment target sits among peer trials
210 245th of 2000 higher than 1,751 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).